Related Experiment Video
Updated: Aug 10, 2026
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical
H Mori1, T Hanabayashi, Y Yamada
1Department of Obsetrics and Gynecology, Gifu University School of Medicine, Japan.
Abstract:
The interferon-gamma (IFN-gamma) productivity of peripheral blood mononuclear cells (PBMCs) was examined in 30 patients with uterine cervical cancer. The patients under 50 years of age had decreased IFN-gamma production compared with the age-matched controls. The IFN-gamma productivity in the patients over 50 years of age was decreased as well as in the age-matched controls. The proportion of monocytes in PBMCs did not correlate with the IFN-gamma productivity. The prostaglandin E2 (PGE2) productivity of PBMCs increased with the progress of cancer. PGE2 inhibited the IFN-gamma production by PBMCs, and the sensitivity of PBMCs to PGE2 was increased in the patients and controls over 60 years of age. The addition of indomethacin resulted in an increase in IFN-gamma production by PBMCs. These results suggest that the increased production of PGE2 and/or increased sensitivity to PGE2 are responsible for the decreased IFN-gamma production in patients with cervical cancer.
Insights
Cervical cancer patients show reduced interferon-gamma (IFN-gamma) production due to increased prostaglandin E2 (PGE2). This suggests PGE2 plays a key role in the immune dysfunction observed in cervical cancer.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Interferon-gamma (IFN-gamma) is crucial for immune responses.
- Reduced IFN-gamma production is observed in various cancers, including cervical cancer.
- Prostaglandin E2 (PGE2) is known to modulate immune cell function.
Purpose of the Study:
- To investigate the relationship between IFN-gamma production and cervical cancer.
- To explore the role of prostaglandin E2 (PGE2) in regulating IFN-gamma production in cervical cancer patients.
- To identify potential mechanisms underlying immune suppression in cervical cancer.
Main Methods:
- Assessed IFN-gamma production in peripheral blood mononuclear cells (PBMCs) from cervical cancer patients and age-matched controls.
- Measured prostaglandin E2 (PGE2) production by PBMCs.
- Evaluated the effect of PGE2 on IFN-gamma production and the impact of indomethacin (a PGE2 inhibitor).
Main Results:
- PBMCs from cervical cancer patients exhibited decreased IFN-gamma production, particularly in those under 50.
- PGE2 production by PBMCs increased with cancer progression.
- PGE2 inhibited IFN-gamma production, and PBMCs showed increased sensitivity to PGE2 in older individuals (>60 years).
- Indomethacin treatment enhanced IFN-gamma production.
Conclusions:
- Increased PGE2 production and/or heightened sensitivity to PGE2 contribute to diminished IFN-gamma levels in cervical cancer.
- PGE2 is a significant factor in the immune suppression associated with cervical cancer.
- Targeting PGE2 pathways may offer therapeutic potential for cervical cancer immunotherapy.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
10:10Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Related Concept Videos
01:27Cytomegalovirus Disease
01:30Inhibitors of Viral Protein Synthesis